CellCentric: Venture Capital Funding History
CellCentric
To add a bio or update company history, please click update information.
News from CellCentric
CellCentric
6 May 2026
CellCentric raises a £160m Series D led by Venrock Healthcare Capital Partners for oral drug designed to treat multiple myeloma and other cancers
CellCentric develops inobrodib, an oral drug designed to treat multiple myeloma and other cancers. The treatment is intended to provide a new option for patients, including those who have already undergone multiple lines of therapy.
CellCentric
19 May 2025
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
CellCentric
- Life Sciences
- Cambridge, United Kingdom
- £250m
- cellcentric.com
- Update Information
More venture news
- 26 Oct 2026
adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026
imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026
OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
